Introduction {#s1}
============

Epstein-Barr virus (EBV) is associated with the development of numerous lymphomas including Burkitt\'s (BL), post-transplant, Hodgkin and certain NK and T-cell lymphomas. EBV was discovered in BL biopsies from sub-Saharan Africa ([@bib13]), where BL is endemic (eBL) and almost always EBV associated. BL also occurs world-wide as sporadic BL (sBL) and immunodeficiency-associated BL, where EBV positivity is approximately 20% and 60%, respectively ([@bib38]). Irrespective of origin or EBV status, the defining feature of BL is a chromosomal translocation involving *MYC* on chromosome 8 and an immunoglobulin (*IG)* gene. *MYC* translocations detected in BL involve either the *IG* heavy, or lambda or kappa light chain loci on chromosomes 14, 2 or 22 respectively. t(8:14) translocations occur in 85% of BL cases ([@bib7]). The position of the *MYC/IG* translocation breakpoint is usually far 5' of *MYC* in endemic (EBV positive) BL. In sporadic BL, breakpoints are in the first exon or intron, implicating different, but unknown, mechanisms in their generation ([@bib43]; [@bib54]). The placement of *MYC* adjacent to highly active regulatory regions at these *IG* loci leads to constitutive high-level *MYC* expression and the uncontrolled proliferation of BL cells. Despite intensive study, the role of EBV in the development of BL is still unclear.

The oncogenic potential of EBV is evident from its potent transforming activity in vitro. On infection, resting B lymphocytes are growth-transformed into permanently proliferating lymphoblastoid cell-lines (LCLs). In common with other herpesviruses, EBV establishes a latent infection in infected cells. Nine viral latent proteins are expressed in EBV-immortalised LCLs; six Epstein-Barr nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and three latent membrane proteins (LMP1, 2A and 2B). EBNA2 and the EBNA3 family of distantly-related transcription factors (TF) (EBNA3A, EBNA3B and EBNA3C) play important roles in the transcriptional reprogramming of host B cells. The actions of these four EBV TFs results in the deregulation of numerous cellular genes involved in the control of B-cell growth and survival ([@bib75], [@bib77]; [@bib57]; [@bib35]; [@bib39]; [@bib21]; [@bib69]). EBNA2, EBNA3A and EBNA3C are required for B-cell immortalisation and the continuous proliferation of infected cells ([@bib9]; [@bib63]; [@bib36], [@bib37]; [@bib29]). These TFs cannot however bind DNA directly; they control gene transcription through interactions with cellular DNA-binding proteins (e.g. RBP-Jκ and PU.1) ([@bib23]; [@bib34]; [@bib66], [@bib67]; [@bib50]; [@bib33]; [@bib76]; [@bib51]). Following initial B-cell transformation in vivo, EBV-infected cells sequentially reduce the number of latent genes they express to enable progression through the B-cell differentiation pathway ([@bib61]). This allows entry into the memory B-cell compartment, where the virus persists. Many EBV-associated tumour cells display restricted patterns of viral latent gene expression that may reflect the differentiation state of the neoplastic precursor cell.

During B-cell transformation by EBV, EBNA2 plays a key role in upregulating numerous genes involved in driving cell proliferation, including the proto-oncogene *MYC* ([@bib25]). Whether EBNA2 activation of *MYC* contributes to the genesis of the *MYC* translocation in BL cells however, is not known. EBNA2 contains an acidic activation domain and mediates gene activation by binding histone acetyl transferases and chromatin remodellers (reviewed in ([@bib28]). EBNA3A, EBNA3B and EBNA3C individually and co-operatively activate and repress cellular gene expression ([@bib69]; [@bib39]; [@bib21]). EBNA3B is dispensable for B-cell immortalisation by EBV, but appears to play a role in suppressing tumour formation in vivo, since its loss accelerates lymphoma development ([@bib62]; [@bib70]). The role of EBNA3A and EBNA3C as cellular gene repressors has been most extensively studied (reviewed in ([@bib2]). These two viral TFs work cooperatively to silence key tumour suppressor gene. These include the cyclin-dependent kinase inhibitor p16^INK4a^ and the pro-apoptotic Bcl-2 family binding protein Bim (*BCL2L11*) ([@bib55]; [@bib4]). EBNA3A/EBNA3C directed silencing is associated with the recruitment of polycomb repressor complex 1 and 2 (PRC1, 2) and the deposition of the histone H3 lysine 27 trimethyl mark (H3K27me3) ([@bib39], [@bib40]; [@bib45], [@bib46]; [@bib55]; [@bib27]) At *BCL2L11*, PRC-mediated repression leads to longer-term silencing through the accumulation of CpG promoter methylation ([@bib46]).

By activating *MYC* to drive cell proliferation and counteracting *MYC*-triggered apoptosis by silencing *BCL2L11,* EBV TFs are manipulating the same pathways that are deregulated in non-viral lymphomas. In fact, lymphomagenesis only occurs in the presence of deregulated *MYC* expression when the p53-MDM2-p14^ARF^ or *BCL2L11* apoptotic axes are disabled (reviewed in [@bib60]). The mechanisms through which *MYC* and *BCL2L11* are deregulated by EBV TFs however, are not fully defined. Genome-wide analyses indicate that binding of long-range regulatory elements by EBNA2 and EBNA3 proteins plays a key role in cellular gene reprogramming ([@bib40]; [@bib78]; [@bib52]; [@bib22]; [@bib79]; [@bib39]). Indeed, upstream *MYC* enhancer regions bound by EBNA2 have been identified ([@bib78]). *MYC* is one of the most commonly deregulated oncogenes in human cancers and the mapping of multiple cancer risk loci and regions of focal amplification to *MYC* enhancer regions provides strong evidence that inappropriate *MYC* expression can result from the perturbation of long-range control ([@bib73]; [@bib1]; [@bib64]; [@bib48]; [@bib53]; [@bib74]; [@bib20]). *BCL2L11* silencing by EBV has only been studied in the context of EBNA3A and EBNA3C binding to the gene promoter ([@bib40]; [@bib45]), but interestingly, inactivation of a murine-specific *BCL2L11* enhancer has recently been reported in B lymphoblastic leukaemia ([@bib68]). This indicates that enhancer control of *BCL2L11* may be important in other contexts and may be a target for disruption in tumour cells.

Here we demonstrate that EBV EBNA2 upregulates *MYC* by activating specific upstream enhancers. This promotes upstream and reduces downstream enhancer-promoter interactions. These *MYC* enhancer interactions in EBV-infected cells are dependent on the chromatin remodelling function of SWI/SNF. At *BCL2L11*, we show that the EBV repressors EBNA3A and EBNA3C inactivate a newly-described enhancer-promoter hub in a manner dependent on the activity of PRC2. Lymphomagenesis by EBV therefore involves the hijack and reorganisation of large-scale enhancer hubs through the recruitment of specific cellular co-factors.

Results {#s2}
=======

The EBV TF EBNA2 targets tumour-associated superenhancers at *MYC* {#s2-1}
------------------------------------------------------------------

To study the mechanism of *MYC* activation by the EBV TF EBNA2, we examined EBNA2 binding at the *MYC* locus using ChIP-sequencing data we obtained previously from two EBV-infected cell lines ([@bib17]; [@bib40]). These included the EBV-transformed lymphoblastoid cell-line GM12878 (ENCODE Tier 1) generated by in vitro infection of resting B cells and the EBV-positive BL cell line Mutu III ([@bib14]). The Mutu III line is derived from a BL tumour cell line (Mutu I) which underwent broadening of its virus latent gene expression profile in culture. Both cell-lines therefore express the full panel of EBV latent genes, including EBNA2. We found that EBNA2 bound multiple elements both upstream (−556, −428, and −186/168 kb) and downstream (+450, +570, +900 kb and +1.8 Mb) from *MYC* ([Figure 1A and B](#fig1){ref-type="fig"}). Upstream regions bound by EBNA2 in particular, have H3K27 acetylation (H3K27ac) signals characteristic of active enhancers ([Figure 1C](#fig1){ref-type="fig"}). In fact all regions bound by EBNA2, apart from the +900 kb enhancer, are classified as super-enhancers in numerous cancer cell lines and/or primary cells (dbSUPER, <http://bioinfo.au.tsinghua.edu.cn/dbsuper/> \[[@bib30]\]) ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Super-enhancers (SE) are large lineage-specific regulatory elements typically comprising multiple TF binding sites ([@bib71]). The −556 and −428 regions also contain susceptibility loci for chronic lymphocytic leukaemia (CLL) and prostate cancer (rs2466024, rs2466035, rs18814048, rs16902094 and rs445114) ([@bib56]; [@bib15], [@bib16]). EBV therefore targets *MYC* enhancers that function in multiple cell-type specific and tumourigenic contexts.10.7554/eLife.18270.003Figure 1.EBNA2 binding induces directional reorganisation of *MYC* promoter-enhancer interactions.(**A**) EBNA2 ChIP-sequencing reads in EBV-infected GM12878 cells (**B**) in EBV positive Mutu III BL cells (that express all latent EBV proteins). (**C**) H3K27ac signals in GM12878 from ENCODE. Numbering indicates the location of the major enhancer clusters relative to the *MYC* transcription start site. (**D**) Sequencing reads from circularised chromosome conformation capture-sequencing (4C-seq) using the *MYC* promoter as bait in ER-EB 2.5 cells expressing an EBNA2-ER fusion protein cultured in the absence of β-estradiol (-EBNA2). Reads shown are from one of two replicates. The scale bar shows reads per 10 kb window per million reads of sequencing library. (**E**) 4C-seq data from cells incubated in the presence of β-estradiol (+EBNA2). (**F**) Subtraction of -EBNA2 4C-sequence reads from +EBNA2 4C-sequence reads. The scale bar shows the normalised interaction read count difference (see Materials and methods for more details). Asterisks indicate the positions of CTCF sites. (**G**) Capture Hi-C sequencing reads using a *MYC* promoter bait and a CD34+ haemopoietic progenitor cell Hi-C library. Arrows denote positions where statistically significant *MYC* interactions correspond to EBNA2 binding sites. The scale bar shows reads for five merged consecutive genome fragments per million reads of sequencing library. (**H**) *MYC* promoter Capture Hi-C reads obtained from a GM12878 CHi-C libary.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.003](10.7554/eLife.18270.003)10.7554/eLife.18270.004Figure 1---figure supplement 1.*MYC* mRNA induction in ER-EB 2.5 cells.RT-QPCR analysis of *MYC* mRNA expression in ER-EB 2.5 cell samples used for 4C-seq analysis. Cells were cultured in the absence of β-estradiol for 4 days and then for a further 17 hr with (+EBNA2) or without β-estradiol (-EBNA2). Signals were normalised to *GAPDH* mRNA levels. Results show the mean ± standard deviation of QPCR duplicates.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.004](10.7554/eLife.18270.004)

EBNA2 induces large-scale directional reorganisation of *MYC* promoter-enhancer interactions {#s2-2}
--------------------------------------------------------------------------------------------

Although EBNA2 enhances the association of the −428 *MYC* SE with the *MYC* promoter ([@bib78]), there is no information on how the targeting of multiple upstream and downstream long-range *MYC* enhancers by EBNA2 affects enhancer-promoter interactions across the entire *MYC* locus. We examined this using a 4C-sequencing approach.

We used a *MYC* promoter fragment as bait to capture interacting regions in an EBV-transformed LCL expressing a conditionally-active oestrogen receptor-EBNA2 fusion protein (ER-EB 2.5) ([@bib29]). In these cells, EBNA2 can be reversibly inactivated through the withdrawal and re-addition of oestrogen to the culture medium, providing a useful system in which to study the effects of EBNA2 on gene transcription. Re-addition of β-estradiol to ER-EB 2.5 cells cultured for 4 days in its absence, upregulated *MYC* as previously described ([@bib25]) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and resulted in the substantial directional reorganisation of interactions between EBNA2-bound regions and the *MYC* promoter ([Figure 1D--F](#fig1){ref-type="fig"}). In the presence of functional EBNA2, *MYC* promoter interactions with upstream elements, including the −556, −428, and −186/168 kb regions were increased. In contrast, interactions with downstream elements, including the +450 kb, +570 kb and +1.8/1.9 Mb regions were decreased ([Figure 1D--F](#fig1){ref-type="fig"}). Subtraction of 4C-sequencing reads obtained in the absence of functional EBNA2 from those obtained in its presence demonstrated the clear directionality of EBNA2-directed *MYC* reorganisation ([Figure 1F](#fig1){ref-type="fig"}). The high frequency of upstream enhancer interactions with the *MYC* promoter in EBV-infected cells was confirmed in genome-wide capture Hi-C data from GM12878 cells ([Figure 1H](#fig1){ref-type="fig"}). The GM12878 interaction profile contrasts with that obtained from CD34+ haemopoietic progenitor cells ([Figure 1G](#fig1){ref-type="fig"}) ([@bib41]) and leukaemic cells ([@bib53]), where interactions with the +1.8/1.9 Mb enhancers dominate.

We used chromosome conformation capture (3C) to verify the effects of EBNA2 on upstream *MYC* promoter-enhancer interactions ([Figure 2](#fig2){ref-type="fig"}). We detected 2--3-fold increases in promoter interaction frequency in the presence of EBNA2 for the largest EBNA2 binding peak in the −556 SE and for the four EBNA2 peaks in the −186/168 region ([Figure 2C and D](#fig2){ref-type="fig"}). EBNA2 effects on −428 SE interactions have been documented previously ([@bib78]). 4C-sequencing analysis also identified a distinct region within the −556 SE that displayed reduced *MYC* promoter interactions in the presence of EBNA2 ([Figure 1F](#fig1){ref-type="fig"}). A 2.6-fold decrease in the frequency of interactions between this region and the *MYC* promoter was confirmed using 3C ([Figure 2C](#fig2){ref-type="fig"}). This region contains three binding sites for the chromatin boundary and looping factor CTCF ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Two of these CTCF sites are located adjacent to one another and immediately upstream of the main −556 SE EBNA2 binding peak that shows increased promoter interactions in the presence of EBNA2. CTCF binding may therefore delineate a chromatin interaction boundary. All three CTCF sites are bound by CTCF and components of the chromatin looping complex cohesin (SMC3 and RAD21) in GM12878 cells ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Using 3C, we investigated whether EBNA2 influenced interactions between these CTCF sites to change the three-dimensional arrangement of promoter interactions in this region. We found a four-fold increase in interactions between CTCF site-containing fragments in the presence of EBNA2 ([Figure 2E](#fig2){ref-type="fig"}). These data indicate that the process of *MYC* activation by EBNA2 through the directed reorganisation of upstream *MYC* chromatin promotes CTCF site interactions. This results in the looping out of this specific region from the enhancer-promoter chromatin hub and presumably facilitates other upstream enhancer-promoter interactions.10.7554/eLife.18270.005Figure 2.Chromosome conformation capture (3C) confirms EBNA2-induced changes at *MYC* and detects altered CTCF site interactions.(**A**) EBNA2 binding at the −556 super-enhancer region. The positions of the HindIII restriction enzyme sites and the primers used for 3C are indicated. Red arrows indicate the position of the *MYC* enhancer primers used for promoter interaction analysis. Blue arrows indicate the position of the CTCF site primers used to analyse CTCF site interactions. Asterisks indicate the position of CTCF sites. There are two adjacent sites at the 3' end of the region (see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Primer design is unidirectional ([@bib42]). Purple and green lines indicate the regions that show reduced or increased interactions with the *MYC* promoter in 4C, with the transition area displaying a mix of increased and decreased interactions indicated by the checked line (see [Figure 1](#fig1){ref-type="fig"}). (**B**) EBNA2 binding and *MYC* enhancer primer positions in the −186/168 enhancer region (**C**) 3C analysis of interactions between the indicated −556 super-enhancer regions and the *MYC* promoter in the absence or presence of EBNA2 in ER-EB 2.5 cells. Promoter interactions with a region upstream of the −556 super-enhancer not bound by EBNA2 were analysed as a control (Con). Results show the mean ± standard deviation of signals from duplicate PCRs. (**D**) 3C analysis of interactions between the indicated EBNA2-bound −186/168 enhancer regions and the *MYC* promoter in the absence or presence of EBNA2. Control interaction analysis (Con) as in **C**. (**E**) 3C analysis of interactions between the CTCF sites in the −556 super-enhancer region in the absence and presence of EBNA2. CTCF site 2 interactions with the upstream control region were also analysed (Con).**DOI:** [http://dx.doi.org/10.7554/eLife.18270.005](10.7554/eLife.18270.005)10.7554/eLife.18270.006Figure 2---figure supplement 1.CTCF and Cohesin binding in the *MYC* -556 super-enhancer region.(**A**) EBNA2 ChIP-sequencing reads in the GM12878 LCL and (**B**) Mutu III BL cells in the −556 region (as in [Figure 2](#fig2){ref-type="fig"}). ENCODE GM12878 ChIP-sequencing data for CTCF (**C**) and the cohesin subunits SMC3 (**D**) and RAD21 (**E**). (**F**) HindIII restriction enzyme sites and the location of the CTCF site primers used for 3C analysis ([Figure 2](#fig2){ref-type="fig"}). Asterisks indicate the position of three CTCF consensus binding motifs.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.006](10.7554/eLife.18270.006)

We conclude that EBNA2 activation of *MYC* is associated with the large-scale directional reorganisation of the *MYC* enhancer hub. EBNA2 increases upstream enhancer interactions, reduces downstream enhancer interactions and alters interactions between CTCF sites.

*MYC* chromatin reorganisation on EBV infection differs to that induced by physiological B-cell activation {#s2-3}
----------------------------------------------------------------------------------------------------------

EBV infection of naïve B cells results in B-cell activation in a manner that resembles physiological B-cell activation by CD40 ligand (CD40L) and IL-4. B-cell activation by CD40L/IL-4 however results in short-term proliferation whereas EBV-infected B cells grow out into immortal cell-lines. We used 4C-sequencing to determine whether infection of resting B cells by EBV induced the same changes in *MYC* enhancer interactions observed in EBV-infected cell lines. We also examined whether the effects of EBV on *MYC* were distinct from any changes induced by B-cell activation by CD40L/IL-4. We found that in naïve CD19+ B cells, the *MYC* promoter interacted with the −556, −428, +450 and +570 kb enhancer regions ([Figure 3B](#fig3){ref-type="fig"}). This is consistent with the existence of some baseline 'static' enhancer-promoter interactions in resting cells, and the classification of the −556 region as a SE in CD19+ B cells ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). *MYC* mRNA levels increased to maximum levels 48 hr post-EBV infection ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). 4C-sequencing carried out at this time point detected increases in interactions between all upstream enhancers and intervening regions and the *MYC* promoter ([Figure 3B,C and E](#fig3){ref-type="fig"}). This is consistent with the effects we observed on EBNA2 activation in the LCL ([Figure 1](#fig1){ref-type="fig"}). We also observed reduced interactions between the +450, +570 kb and +900 kb enhancers and the *MYC* promoter on EBV infection consistent with our LCL data ([Figure 3B,C and E](#fig3){ref-type="fig"}). In contrast to our previous observations however, we detected some small localised increases in interactions with regions downstream from the *MYC* promoter ([Figure 3B](#fig3){ref-type="fig"}), which may reflect the low level of interactions present in this region in resting B cells ([Figure 3E](#fig3){ref-type="fig"}). In contrast, 48 hr after B-cell activation by CD40L/IL-4 we observed a reverse effect on *MYC* promoter-enhancer interactions ([Figure 3B,D and F](#fig3){ref-type="fig"}). Upstream interactions were reduced and downstream interactions were increased. In particular, the region +235 to +432 kb interacted with the *MYC* promoter at high level. This downstream region is not bound by EBNA2 and does not interact with the *MYC* promoter significantly in EBV-infected cells. This region does however interact at high frequency in CD34+ cells ([Figure 1G](#fig1){ref-type="fig"}). These data therefore highlight specificity in the remodelling of *MYC* promoter-enhancer interactions by different stimuli in B cells. This is particularly evident when the effects of EBV and CD40L/IL-4 on *MYC* promoter interactions are compared ([Figure 3G](#fig3){ref-type="fig"}).10.7554/eLife.18270.007Figure 3.EBV infection of naïve B cells induces directional reorganisation of *MYC* promoter-enhancer interactions.(**A**) EBNA 2 ChIP-sequencing reads in Mutu III BL cells (as in [Figure 1](#fig1){ref-type="fig"}). Interactions captured by 4C-seq using the *MYC* promoter as bait (as in [Figure 1](#fig1){ref-type="fig"}) in uninfected naïve B cells (**B**), B cells 48 hr post-EBV infection (**C**) and B cells 48 hr post-stimulation with CD40L/IL-4 (**D**). Subtraction of 4C-seq reads from uninfected B cells from those obtained from EBV-infected cells (**E**) or CD40L/IL-4 treated cells (**F**). Reads shown are from both replicates combined. The scale bar shows reads per 10 kb window per million reads of sequencing library. (**G**) Subtraction of 4C-seq reads from CD40L/IL4-treated cells from those obtained from EBV-infected cells. The scale bar shows the normalised interaction read count difference.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.007](10.7554/eLife.18270.007)10.7554/eLife.18270.008Figure 3---figure supplement 1.*MYC* mRNA induction on EBV infection.(**A**) RT-QPCR analysis of *MYC* mRNA expression over a B-cell infection time course to determine the optimum time for *MYC* induction. (**B**) RT-QPCR analysis of *MYC* mRNA expression in the naïve, EBV-infected and CD40L/IL-4 B cell samples used for 4C-seq. Signals were normalised to β2-microglobulin mRNA levels as *GAPDH* is induced on B-cell infection. Results show the mean ± standard deviation of QPCR duplicates.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.008](10.7554/eLife.18270.008)

In summary, EBV infection of naïve B cells reconfigures *MYC* chromatin architecture in a manner distinct from physiological B-cell stimulation. EBV infection results in the same selective enhancement of upstream enhancer-promoter interactions observed on EBNA2 activation in EBV-infected cell-lines.

The SWI/SNF ATPase BRG1 is recruited by EBNA2 and is required for upstream enhancer-promoter interactions {#s2-4}
---------------------------------------------------------------------------------------------------------

We next investigated the mechanism of *MYC* activation by EBNA2. In the presence of EBNA2, we found increased levels of H3K27ac across EBNA2-bound enhancer regions, consistent with enhancer activation. EBNA2 increased H3K27ac levels seven-fold at the main *MYC* P2 promoter and 16-fold at the −556 SE ([Figure 4A](#fig4){ref-type="fig"}). BRG1, the ATPase subunit of the chromatin remodeller SWI/SNF, is required for the interaction of the +1.8/1.9 Mb leukaemic-cell *MYC* enhancer with the *MYC* promoter ([@bib53]), so we examined the involvement of BRG1 in EBNA2 activation of *MYC* enhancers. We found that BRG1 associated with specific *MYC* enhancers, with highest levels at the −186/168 enhancer and the −556 SE main peak ([Figure 4B](#fig4){ref-type="fig"}). BRG1 also bound the +1.8 Mb enhancer but at lower levels. EBNA2 increased BRG1 binding at these sites, consistent with the ability of EBNA2 to interact with BRG1 via the Snf5 subunit of SWI/SNF ([@bib72]). Interestingly, EBNA2 reduced BRG1 binding to the region of the −556 SE that is looped out through CTCF site association ([Figure 4B](#fig4){ref-type="fig"}). The effect of EBNA2 on BRG1 binding at upstream regions therefore correlates with the effect of EBNA2 on promoter interaction frequency. We next investigated whether BRG1 was required for the interaction of EBNA2-bound enhancers with the *MYC* promoter in EBV-infected cells. We found that siRNA-mediated BRG1 knockdown in GM12878 cells led to a loss of *MYC* promoter interactions with the −556, −428 and −186/168 enhancers ([Figure 4C and D](#fig4){ref-type="fig"}). 3C did not detect any interactions between the +1.8 Mb region and the *MYC* promoter in the presence or absence of BRG1 (data not shown), consistent with its low-level interaction frequency in EBV-infected cells ([Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}). We conclude that BRG1 is required to maintain the active upstream *MYC* enhancer-promoter hub in EBV-infected B cells.10.7554/eLife.18270.009Figure 4.BRG1 is required for upstream *MYC* enhancer-promoter interactions in EBV-infected cells.(**A**) ChIP-QPCR analysis of H3 acetylation at *MYC* in ER-EB 2.5 cells minus or plus β-estradiol (± EBNA2). Precipitated DNA was analysed using primer sets located at the main EBNA2-bound enhancers. For the −556 SE analysis included a region where decreased interactions were observed (1) and the −556 main peak where increased interactions were observed (3) (see [Figure 2](#fig2){ref-type="fig"}). The signal at a control region not bound by EBNA2 (used for 3C analysis in [Figure 2](#fig2){ref-type="fig"}) was used as a negative control for binding (Con). Mean percentage input signals, after subtraction of no antibody controls, are shown ± standard deviation for two independent ChIP experiments. (**B**) ChIP-QPCR analysis of BRG1 binding at *MYC* in ER-EB 2.5 cells minus or plus β-estradiol (± EBNA2). (**C**) Western blot analysis of BRG1 expression in GM12878 transiently transfected with control or BRG1-specific siRNAs. Actin was used as a loading control. (**D**) Chromosome conformation capture analysis of the interaction of EBNA2-bound upstream enhancerswith the *MYC* promoter in control and BRG1 siRNA transfected GM12878 cells. Results show the mean ± standard deviation of signals from duplicate PCRs.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.009](10.7554/eLife.18270.009)

EBV EBNA 3A and 3C silence *BCL2L11* by disrupting long-range enhancer interactions {#s2-5}
-----------------------------------------------------------------------------------

We previously demonstrated that repression of *BCL2L11* was associated with EBNA3A and 3C-specific binding to the *BCL2L11* promoter ([@bib40]). However, ChIP-sequencing using an antibody that precipitates all EBNA3 proteins also revealed the presence long-range EBNA3 binding sites at the *BCL2L11* locus ([Figure 5A](#fig5){ref-type="fig"}) ([@bib39], [@bib40]). These include three major sites upstream of *BCL2L11* (up to −374 kb) that lie within the neighbouring acyl-CoA oxidase-like gene *ACOXL* and three sites 310 to 587 kb downstream of *BCL2L11* ([Figure 5A](#fig5){ref-type="fig"}). These elements represent new putative *BCL2L11* enhancers that we designated enhancers 1--6. Enhancers 1, 4, and 6 are predicted as SEs in blood-derived primary cells or cell-lines (<http://bioinfo.au.tsinghua.edu.cn/dbsuper/> \[[@bib30]\]) indicative of a functional role. In fact, enhancer 4 is predicted to have SE function in 30 different cell types, 22 of which are blood-derived primary or cancer cells ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Enhancer 4 may therefore play a key role in *BCL2L11* control in blood cells. EBNA3 binding sites are also present in the *ACOXL* promoter and the adjacent *BUB1* promoter.10.7554/eLife.18270.010Figure 5.EBNA3A and 3C repress *BCL2L11* by inactivating a long-range enhancer hub.(**A**) ChIP-sequencing reads for EBNA3A/3B/3C at the *BCL2L11* locus in Mutu III BL cells. The major EBNA3-bound sites are numbered 1--6 and their location relative to the transcription start site of the *BCL2L11* promoter is indicated. Binding peaks at the *ACOXL* (Ap) and *BCL2L11* promoters (Bp) are also indicated. ChIP-QPCR analysis of EBNA3A binding (**B**) EBNA3B binding (**C**) and EBNA3C binding (**D**) in the EBV-negative BL31 BL cell-line infected with wild-type recombinant EBV (BL31 wtBAC2). Precipitated DNA was analysed using primer sets located at EBNA3A/3B/3C binding sites (binding at the *BCL2L11* promoter has been previously characterised \[[@bib40]\]). The signal at the transcription start site of *PPIA* was used as a negative control for binding (−).The previously characterised *CTBP2* binding site was used as a positive control for EBNA3A and EBNA3C binding (+). The *RUNX3* superenhancer was used as a positive control for EBNA3B binding ([@bib17]). Mean percentage input signals, after subtraction of no antibody controls, are shown ± standard deviation for two independent ChIP experiments. (**E**) Chromosome conformation capture (3C) analysis of *BCL2L11* promoter interactions between enhancers 1--6 and the *ACOXL* promoter in the EBV-negative BL cell-line BL31 and in BL31 cells infected with wild-type recombinant EBV (wt BAC2), EBNA3A knock-out EBV (EBNA3AKO), EBNA3B knock-out EBV (EBNA3BKO) and EBNA3C knock-out EBV (EBNA3CKO). A control region (**C**) not bound by the EBNAs was also included in the analysis. Positive controls show amplification of a digested and ligated genomic PCR fragment library containing all ligation junctions. The expression status of *BCL2L11* in each line is indicated on the right. The red asterisks indicates non-specific amplification products of incorrect size.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.010](10.7554/eLife.18270.010)10.7554/eLife.18270.011Figure 5---figure supplement 1.*ACOXL* is repressed by EBNA3C.LCLs expressing HT-EBNA3C were grown in the presence of HT for 25 days (EBNA3C on) and then HT was washed off and cells cultured in its absence for 21 days (EBNA3C off). Cells then either had HT re-added and were cultured for up to another 14 days to re-instate EBNA3C function or were maintained in HT for a further 10 days to maintain EBNA3C inactivity. (**A**) *ACOXL* mRNA levels were determined by RT-PCR and signals were normalised to *GAPDH* and expressed relative to the expression level at the start of the experiment. Results show the mean ± standard deviation for duplicate QPCR samples from a representative experiment. (**B**) *ADAMDEC1* mRNA analysis. *ADAMDEC1* ([@bib39]) is a known EBNA3C repressed gene and serves as a control for the EBNA3C-HT withdrawal and add back.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.011](10.7554/eLife.18270.011)10.7554/eLife.18270.012Figure 5---figure supplement 2.Additional *BCL2L11* chromosome conformation capture controls.(**A**) EBNA3A/3B/3C binding at the *BCL2L11* locus as in [Figure 5](#fig5){ref-type="fig"} showing the locations of the primers used for 3C analysis. Primer design is unidirectional. (**B**) 3C analysis in BL31 cells to examine *BCL2L11* promoter interactions with additional intervening control regions where there is no EBNA3A or EBNA3C binding (C2, C3, C4). (**C**) Control 3C analysis using BL31 cell chromatin that was digested but incubated in the absence of ligase (-ligase). Analysis was performed using primers to detect enhancer-promoter and promoter-promoter interactions as in [Figure 5](#fig5){ref-type="fig"} and using the additional control primers. Red asterisks indicate the position of non-specific PCR products of the incorrect sizes (verified by sequencing).**DOI:** [http://dx.doi.org/10.7554/eLife.18270.012](10.7554/eLife.18270.012)

ChIP-QPCR using specific antibodies demonstrated that only EBNA3A and EBNA3C bind to *BCL2L11* long-range elements ([Figure 5B--D](#fig5){ref-type="fig"}), consistent with *BCL2L11* silencing through the combined actions of EBNA3A and EBNA3C, but not EBNA3B ([@bib4]). Only EBNA3C bound at significant levels to *ACOXL* sites, with most binding at enhancers 2 and 3 ([Figure 5B--D](#fig5){ref-type="fig"}). Although *ACOXL* was not expressed in most B cell-lines we examined, we found that inactivation of EBNA3C in an LCL expressing a conditionally-active EBNA3C-hydroxytamoxifen fusion protein led to increased *ACOXL* expression ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This points to a role for EBNA3C as a repressor of *ACOXL*.

To determine whether any of the long-range EBNA3A/3C binding sites interact with the *BCL2L11* promoter, we performed 3C analysis in a previously described BL cell-line series (BL31) ([@bib4]). BL31 cells derive from an EBV-negative BL and have been used to study the effects of EBV and EBNA3A, 3B and 3C on cellular gene expression by infecting them with recombinant wild-type or knock-out EBVs ([@bib4]; [@bib69]; [@bib40]). The co-operative repression of *BCL2L11* by EBNA3A and EBNA3C was first described and characterised in this cell line series ([@bib4]; [@bib45]), providing an excellent background in which to study the effects of these EBV repressors on *BCL2L11* enhancer-promoter interactions. Using the *BCL2L11* promoter as bait, we found that in uninfected BL31 cells (where *BCL2L11* is expressed), the *ACOXL* promoter and all long-range elements (apart from enhancer 1 within *ACOXL*) interacted with the *BCL2L11* promoter ([Figure 5E](#fig5){ref-type="fig"}). An active enhancer-promoter hub encompassing *ACOXL* therefore directs *BCL2L11* expression in these cells. 3C did not detect any interactions between the *BUB1* promoter and the *BCL2L11* promoter (data not shown). We detected no interactions between the *BCL2L11* promoter and four intervening control regions not bound by EBNA3A or EBNA3C, indicating that the enhancer-promoter interactions we detected were specific. ([Figure 5E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In contrast to EBV-negative BL31 cells, in BL31 cells infected with either wild-type EBV or EBNA3B knock-out EBV (where *BCL2L11* is repressed), we observed a loss of all promoter-enhancer interactions ([Figure 5E](#fig5){ref-type="fig"}). Accordingly, in cells infected with EBNA3A or EBNA3C knock-out viruses, *BCL2L11* was expressed and all enhancer-promoter interactions were preserved. *BCL2L11* silencing by EBNA3A and EBNA3C is therefore associated with the inactivation of an active enhancer-promoter hub encompassing *ACOXL*.

We next investigated whether the disruption of enhancer-promoter interactions by EBNA3A and EBNA3C was also associated with enhancer chromatin inactivation. Using ChIP-QPCR we examined the binding of the PRC2 H3K27 methyltransferase EZH2 across EBNA3-bound sites. Consistent with previous observations ([@bib45]), we found that EZH2 was associated with the *BCL2L11* promoter in cells infected with viruses expressing EBNA3A and EBNA3C (wt BAC2 and EBNA3B KO, [Figure 6A](#fig6){ref-type="fig"}). We also detected EZH2 binding to all enhancers targeted by EBNA3A and EBNA3C and to the *ACOXL* promoter ([Figure 6A](#fig6){ref-type="fig"}). These results are consistent with enhancer inactivation either initiated by, or resulting in, PRC-associated chromatin silencing. EBNA3A and EBNA3C have been shown to induce the deposition of the PRC silencing mark H3K27me3 across the *BCL2L11* promoter ([@bib46]). H3K27me3 ChIP-seq data from GM12878 cells (that express EBNA3A and EBNA3C) however, also demonstrates the presence of characteristically broad domains of H3K27me3 that coincide with the locations of the EBNA3-bound *BCL2L11* enhancers ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). In fact a large H3K27me3 domain encompasses the entire *ACOXL* gene and the *BCL2L11* promoter ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The corresponding absence of active H3K27ac marks in these regions is consistent with silencing of both genes.10.7554/eLife.18270.013Figure 6.EZH1/2 activity is required for the disruption of the *BCL2L11* and *ACOXL* enhancer hub.(**A**) ChIP-QPCR analysis of EZH2 binding in the BL31 cell line series used in [Figure 5](#fig5){ref-type="fig"}. The expression status of *BCL2L11* in each cell line is shown. (**B**) RT-QPCR analysis of *BCL2L11* mRNA expression in EBV negative BL31 cells or BL31 cells infected with wild-type recombinant EBV (BL31 wtBAC2) treated with the EZH2 inhibitor UNC1999 for 8 hr. Signals were normalised to *GAPDH* mRNA levels and expressed as fold increase compared to untreated cells. (**C**) *BCL2L11* mRNA expression in BL31 and BL31 wtBAC2 cells treated with UNC1999 for 18 hr. (**D**) Caspase 3/7 activity in BL31 or BL31 wtBAC2 cells treated with UNC1999 for 8 hr. Caspase signals shown are corrected for the number of live cells. (**E**) Caspase 3/7 activity in cells treated for 18 hr. (**F**) Chromosome conformation capture analysis of *BCL2L11* promoter interactions between enhancers 1--6 and the *ACOXL* promoter in BL31 wtBAC2 cells treated with UNC1999 for 24 hr. Primers are as in [Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.18270.013](10.7554/eLife.18270.013)10.7554/eLife.18270.014Figure 6---figure supplement 1.EBNA3A and EBNA3C-bound enhancers at the *BCL2L11/ACOXL* locus are within H3K27me3 repressed domains.(**A**) EBNA3A/3B/3C ChIP-sequencing from Mutu III BL cells as in [Figure 5](#fig5){ref-type="fig"}. (**B**) H3K27me3 ChIP-sequencing signals in GM12878 cells (ENCODE). Boxes show the H3K27me3 domain encompassing the entire *ACOXL* gene and the *BCL2L11* promoter (and enhancers 1--3) and the domains that encompass enhancers 4, 5 and 6.(**C**) H3K27Ac ChIP-sequencing signals in GM12878 (ENCODE).**DOI:** [http://dx.doi.org/10.7554/eLife.18270.014](10.7554/eLife.18270.014)

To determine whether *BCL2L11* silencing by EBV could be reversed through the loss of EZH2 activity, we treated EBV-negative BL31 cells and EBV-infected BL31 wt BAC2 cells with the EZH1/2 inhibitor UNC1999. In EBV-infected BL31 cells, *BCL2L11* mRNA expression increased up to 3.6- and 5.4-fold after 8 and 18 hr treatment with UNC1999, consistent with the inhibition of PRC2-mediated gene repression ([Figure 6B and C](#fig6){ref-type="fig"}). In contrast, treatment of EBV-negative BL31 cells with UNC1999 resulted in only 1.8 to 2.7 fold increases in *BCL2L11* expression after 8 and 18 hr, respectively ([Figure 6B and C](#fig6){ref-type="fig"}). Since *BCL2L11* is not repressed by EBV in BL31 cells, these small increases may reflect the fact that even though the gene is expressed, further de-repression can be achieved through EZH1/2 inhibition. Consistent with increased *BCL2L11* expression and the pro-apoptotic function of *BCL2L11*, EBV-infected BL31 cells treated with UNC1999 also displayed large increases in Caspase 3/7 activity ([Figure 6D and E](#fig6){ref-type="fig"}). Caspase 3/7 activity was very low in EBV-negative BL31 cells but increased slightly in the presence of UNC1999, consistent with the smaller increases in *BCL2L11* expression. These data therefore indicate that PRC-mediated silencing of *BCL2L11* by EBNA3A and EBNA3C can be reversed by EZH1/2 inhibition and results in the induction of apoptosis.

To assess the effect of EZH2 inhibition on *BCL2L11* promoter interactions, we performed 3C analysis of the *BCL2L11* locus in EBV-infected BL31 cells following UNC1999 treatment. We found that treatment with 5 or 10 µM UNC1999 led to increased interactions between the *BCL2L11* promoter and all enhancers, and between the *BCL2L11* and *ACOXL* promoters ([Figure 6F](#fig6){ref-type="fig"}). These data indicate that EZH1/2 activity is required for the inactivation of *BCL2L11* enhancers and *BCL2L11* silencing in EBV-infected cells.

We conclude that the increased cell survival that results from EBV EBNA3A and EBNA3C silencing of *BCL2L11* involves the recruitment of EZH2 and the inactivation of a long-range active enhancer hub encompassing the neighbouring *ACOXL* gene.

Discussion {#s3}
==========

B-cell immortalisation by EBV plays a central role in the development of numerous B-cell lymphomas and is required for the persistence of EBV in infected hosts. EBNA2 is essential for B-cell immortalisation and the continuous growth of EBV-infected cells ([@bib9]; [@bib29]). Upregulation of *MYC* by EBNA2 ([@bib25]) plays a key role in stimulating B-cell proliferation early in infection, promoting immortalisation. Our data now show that EBV manipulates *MYC* enhancer function to drive tumourigenesis, inducing directional remodelling of enhancer-promoter interactions over 3 Mbs. EBV promotes upstream promoter-enhancer interactions and decreases downstream interactions. The *MYC* enhancer interaction landscape in EBV-infected cells is therefore distinct from leukaemia cells, where downstream enhancers are the major controllers of *MYC* transcription ([@bib20]; [@bib53]).

Whether *MYC* activation by EBNA2 also plays a role in predisposing immortalised infected cells to the *MYC* translocations that characterise EBV-positive BL has not been explored. In fact, the role of EBV in the pathogenesis of BL remains an enigma, since the defining feature of BL is a *MYC/IG* translocation rather than the presence of EBV. It has been proposed that EBV may contribute to BL simply by providing a pool of cells undergoing deregulated growth, in which a genetic accident becomes more likely. Most evidence however, now points to a role for EBV in providing a survival advantage to cells that express high-levels of *MYC* by repressing *BCL2L11* (see below). Pro-survival events presumably arise through genetic and epigenetic changes induced by non-viral mechanisms in EBV-negative BLs. Given that the *BCL2L11* repressors EBNA3A and EBNA3C are expressed initially in growth-transformed B cells, but not in BL cells (which express only EBNA1), *BCL2L11* repression is likely an early event that prevents apoptosis driven by the initial activation of *MYC* by EBNA2. Since H3K27me3-mediated *BCL2L11* repression leads to CpG methylation at the *BCL2L11* promoter ([@bib46]) this 'hit-and-run' silencing event would provide a long-lived survival advantage to cells in which a *MYC/IG* translocation may subsequently arise. EBV increases the likelihood of a translocation event through the upregulation of AID by EBNA3C ([@bib26]). The generation of double-strand DNA breaks as a result of aberrant AID activity is strongly implicated in the genesis of *MYC/IG* translocations ([@bib49]; [@bib11]). AID preferentially targets active enhancer regions, so our data implicate the activation of upstream *MYC* enhancers by EBNA2 in predisposing these regions to AID-induced breakpoints in EBV-infected cells.

Interestingly, *MYC-IG* breakpoints in EBV-positive eBL carrying the common t(8;14) translocation are predominantly located far upstream of *MYC* whereas breakpoints in sBL are evenly distributed between the promoter region, the first exon and the first intron ([@bib43]; [@bib54]; [@bib8]; [@bib24]; [@bib47]). When we examined the location of *MYC-IG* breakpoints in eBLs in light of the EBV-induced changes we detected in the chromatin region upstream of *MYC*, we found that previous studies mapped the majority of EBV-positive eBL breakpoints to upstream of the *Eco*RI site 7 kb upstream of *MYC* ([@bib43]; [@bib54]; [@bib47]). Only eight EBV-positive eBLs have had their 5' breakpoints further mapped or sequenced ([@bib18]; [@bib43]; [@bib24]). These seven eBL cell-lines and one eBL biopsy sample have translocation junctions −215 to −46 kb upstream of *MYC* ([@bib18]; [@bib43]; [@bib24]). These upstream eBL breakpoints therefore map to the vicinity of the EBNA2-bound −186/168 enhancer. This region has not previously been studied as a long-range *MYC* control region, but has SE properties in colorectal carcinoma and diffuse large B cell lymphoma cell-lines ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Our data therefore highlight a role for the −186/168 enhancer in the remodelling of upstream *MYC* chromatin that may create a 'hotspot' for eBL breakpoints. In fact all upstream breakpoints (including those more than 7 kb upstream of *MYC* that have not been fully mapped) likely fall within the upstream region that displays increased promoter looping in the presence of EBV. We therefore propose that the EBNA2-directed activation and remodelling of *MYC* upstream chromatin may increase the susceptibility of this region to a translocation event initiated by the off-target activity of activation-induced cytidine deaminase (AID). In contrast to eBL, sporadic BL t(8:14) breakpoints cluster in two regions much further downstream that include the *MYC* promoter (−400 bp to + 150 bp) and a region immediately downstream (+420 bp to +1.2 kb) ([@bib8]). This suggests that specific chromatin changes or other factors contribute to the localisation of *MYC* breakpoints in different regions in the absence of EBV.

Our data also demonstrate that the mechanism of *MYC* activation by EBNA2 through upstream enhancers involves the recruitment of the SWI/SNF ATPase BRG1. Previous studies have demonstrated that AML cell growth is dependent on *MYC* activation by SWI/SNF ([@bib53]). This dependency appears to result from a requirement for BRG1 for the interaction of the +1.8/1.9 Mb (+1.7 Mb in mouse) *MYC* enhancer with the promoter ([@bib53]). In AML cells, BRG1 knockdown decreased downstream enhancer interactions and increased upstream enhancer interactions, suggesting some directionality in the effects of BRG1 on enhancer looping. In EBV-infected cells however, we find that BRG1 is required for the maintenance of upstream enhancer-promoter interactions. Our data are therefore consistent with a model where BRG1-dependent chromatin remodelling is required for *MYC* enhancer-promoter interactions. The specificity of BRG1 dependence however, is determined by which *MYC* enhancers are active in a particular cell-type or context.

Repression of *BCL2L11* is a key strategy employed by EBV to circumvent *MYC-*driven apoptosis and promote survival ([@bib60]). This is consistent with observations that the loss of a single *BCL2L11* allele accelerates lymphoma development in Eµ-*MYC* transgenic mice ([@bib12]). The tumour suppressor role of *BCL2L11* is also supported by its deletion in 40% of mantle cell lymphomas ([@bib59]), silencing through CpG promoter methylation in natural killer cell lymphomas ([@bib32]) and its targeting by the oncogenic miR-32 and miR17-92 microRNAs ([@bib65]; [@bib31]; [@bib3]). We now show that *BCL2L11* repression in B cells results from the inactivation of multiple long-range enhancers. Our previous analysis focused on the low-level binding of the EBV repressors EBNA3A and EBNA3C to the *BCL2L11* promoter ([@bib40]). It is now clear that the *BCL2L11* promoter is controlled through a long-range regulatory hub that is inactivated by EBNA3A and EBNA3C through a process that results in the recruitment of the PRC2 methyltransferase EZH2 and is dependent on EZH1/2 activity. No direct interaction between EBNA3A and EBNA3C and components of the PRC1 or PRC2 transcriptional repressors has been reported to date. PRC-dependent and H3K27me3-associated gene silencing by EBNA3A and EBNA3C has however been convincingly demonstrated at multiple gene loci ([@bib55]; [@bib19]; [@bib27]; [@bib39]; [@bib40]). The mechanism of PRC recruitment by these EBV repressors remains unclear. In fact, time-course studies have shown that the loss of active chromatin marks from gene promoters and enhancers repressed by EBNA3A and EBNA3C precedes the binding of PRCs and the deposition of H3K27me3 ([@bib19]; [@bib27]). PRC recruitment and H3K27me3 deposition may therefore be a secondary and perhaps default event.

At the *BCL2L11* locus, we have identified enhancers that control *BCL2L11* expression in human B cells, that are manipulated by EBV to repress *BCL2L11* in infected B cells. These enhancers have potential roles in *BCL2L11* control in normal and malignant cells ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Interestingly, a murine *BCL2L11* enhancer located 117 kb upstream and within *ACOXL* (but distinct from the EBV-targeted enhancers described here) was recently shown to be disrupted by binding of the TRIM33 transcription cofactor to prevent *BCL2L11*-induced apoptosis in B lymphoblastic leukaemia ([@bib68]). Importantly, we showed that EBV-induced repression of *BCL2L11* through the disruption of enhancer-promoter interactions was reversed by EZH1/2 inhibition and resulted in increased apoptosis. This provides a therapeutic rationale for the use of EZH2 inhibitors in the treatment of EBV-positive lymphomas where *BCL2L11* is repressed. Our work also revealed that the poorly characterised *ACOXL* gene is a target for repression by EBNA3C. Interestingly, *ACOXL* contains two risk loci for CLL ([@bib10]; [@bib6]), one of which (rs13401811 \[[@bib6]\]) maps to a smaller EBNA3A/B/C binding peak between enhancers 1 and 2 that we did not characterise in this study. This raises the possibility that this polymorphism deregulates the function of a *BCL2L11* enhancer. *ACOXL* is also downregulated in prostate cancer tissues ([@bib44]), but further studies are required to confirm any potential role in tumourigenesis.

In summary, we show that EBV-directed lymphomagenesis involves the hijacking of long-range enhancer hubs at *MYC* and *BCL2L11* ([Figure 7](#fig7){ref-type="fig"}). *MYC* enhancer activation by EBV may contribute to the genesis of *MYC* translocations in BL. Enhancer-mediated control of *BCL2L11* may be exploited in other tumourigenic contexts to manipulate cell survival.10.7554/eLife.18270.015Figure 7.Model showing the mechanism of *MYC* activation and *BCL2L11* repression by EBV transcription factors.(**A**) In uninfected B cells, *MYC* promoter interactions with downstream enhancers dominate. *MYC* activation on EBV infection by the EBV TF EBNA2 occurs through the activation of three major clusters of upstream enhancers at −556, −428 and −186/168 kb (indicated by black boxes). This is associated with increased H3K27ac and BRG1 binding. EBNA2 promotes interactions between the *MYC* promoter and these upstream enhancers and reduces interactions with downstream enhancers. As part of this three-dimensional *MYC* enhancer reorganisation, EBNA2 also increases interactions between CTCF-bound regions (asterisks) in the −556 kb super-enhancer. (**B**) *BCL2L11* is repressed on EBV-infection by the EBV repressors EBNA3A and EBNA3C through the inactivation of multiple enhancers in regulatory hub encompassing the *ACOXL* gene. Enhancer inactivation is associated with PRC2 (EZH2) binding, increased H3K27me3 and the loss of enhancer-promoter interactions. Arrows indicate transcription start sites. Genes are indicated as expressed (+) or repressed (−). ACOXL is repressed or expressed at low-level (±).**DOI:** [http://dx.doi.org/10.7554/eLife.18270.015](10.7554/eLife.18270.015)

Materials and methods {#s4}
=====================

Cell lines {#s4-1}
----------

All cell lines were routinely passaged twice-weekly in RPMI-1640 media (Invitrogen, UK) containing 10% Foetal Bovine Serum, Penicillin and Streptomycin (Invitrogen). The EBV-positive latency III BL cell line Mutu III (clone 48) derives from the Mutu I latency I BL cell-line ([@bib14]). Mutu I cells display the 'latency I' restricted form of EBV gene expression characterised by the expression of only EBNA1. Mutu III cell clones arose spontaneously during culture of Mutu I cells and display an expanded latent gene expression pattern (latency III). The EBV-immortalised LCL GM12878 is an ENCODE Tier 1 cell line obtained from the Coriell Cell Repositories (Camden, New Jersey) (RRID: [CVCL_7526](https://scicrunch.org/resolver/CVCL_7526)). The EBV-negative BL31 cell line series infected with wild-type recombinant EBV bacmids or EBNA 3A, 3B and 3C knock-out and revertant bacmids (kindly provided by Prof M. Allday) were cultured with the appropriate selection and supplements, as previously described ([@bib4]). The EBV-immortalised ER-EB 2.5 LCL, expressing a conditionally-active oestrogen receptor (ER)-EBNA2 fusion protein, was provided by Prof B. Kempkes, and was cultured in the presence of β-estradiol ([@bib29]). For β-estradiol withdrawal and add back experiments, ER-EB 2.5 cells were incubated in the absence of β-estradiol for 4 days, and 1 µM β-estradiol was re-added for 17 hr, prior to cell harvest. The LCL expressing conditionally-active EBNA3C is infected with recombinant EBV expressing EBNA3C fused at the C terminus to a 4-hydroxytamoxifen (HT)-sensitive murine oestrogen receptor (LCL 3CHT) and was provided by Prof M. Allday ([@bib55]). For 4-hydroxytamoxifen withdrawal and add back experiments LCL 3CHT cells were initially cultured in the presence of 400 nM of 4-hydroxytamoxifen (Sigma, UK) for 25 days, HT was then washed off and cells cultured for 21 days. HT was then either re-added or cells grown for a further 10 days in HT. For EZH1/2 inhibition, UNC1999 (Sigma) was added to BL31 wtBAC2 cells seeded at a density of 5 × 10^5^ cells/ml, and cells harvested after 24 hr for mRNA and chromosome conformation capture. All cell-lines were verified as mycoplasma free.

Isolation, infection and CD40L-mediated activation of primary resting B cells {#s4-2}
-----------------------------------------------------------------------------

Primary resting B cells were isolated from blood from fresh apheresis cones obtained from the NHSBT under the ethically approved study 14/WM/0001. The Peripheral blood mononuclear cells were isolated by density centrifugation on lymphoprep (Axis Shield, UK) and the B cells were subsequently purified by positive isolation using pan-CD19 Dynabeads (Dynal, ThermoFisher, UK). The Dynabeads were removed from the purified B cells by incubation with Detachabead (Dynal, ThermoFisher). Purified B cells were incubated with 2089 EBV at an MOI of 100 for 1 hr at 37°C and the unbound virus was washed off. One million uninfected purified B cells were cultured in 4 ml of medium supplemented with 50 ng/ml soluble mega CD40L (Enzo, UK) and 50 ng/ml IL4. The infected and CD40L-stimulated B cells were grown in RPMI, 10% FBS and supplemented with penicillin/streptomycin and glutamine.

siRNA knockdown {#s4-3}
---------------

200 nM ON-TARGETplus Human SMARCA4 (BRG1) siRNA (Dharmacon, GE Healthcare, UK; L-010431-00-0005) or ON-TARGETplus siRNA non-targeting siRNA \#1 (Dharmacon, GE Healthcare; D-001810-01-05) were transfected into 5 × 10^6^ GM12878 cells resuspended in buffer T cells using the Neon transfection and 1 pulse of 1300 V for 30 msec. Following transfection the cells were further incubated for 72 hr in normal media without antibiotics.

Caspase 3/7 assay {#s4-4}
-----------------

BL31 and BL31 wtBAC2 cells (100 µl) were seeded into 96 well plates at a density of 20,000 cells/well and cultured for 8 or 18 hours in the presence or absence of UNC1999. An equal volume of Caspase-Glo 3/7 Assay reagent (Promega, UK) was added, and cells were incubated for 30 min at room temperature. Luminescence was measured using a Glowmax multi detection system (Promega).

ChIP-sequencing {#s4-5}
---------------

Previously published EBNA2 and EBNA3A/B/C Mutu III ChIP-sequencing data ([@bib40]) are available via GEO accession number GSE47629 and EBNA2 GM12878 data via accession number GSE76869 ([@bib17]). Note that Mutu III cells have an unmapped *MYC-IG* translocation, but sequence reads are mapped to the intact *MYC* locus. EBNA2 binding sites in Mutu III cells are also detected in GM1278 cells and/or in the IB4 EBV-infected LCL ([@bib78]) so the integrity of binding to these sites seems to be maintained despite their translocation.

ChIP-QPCR {#s4-6}
---------

EBNA3A, EBNA3B and EBNA3C were precipitated as described previously using antibodies specific for each EBNA ([@bib40]). ChIP for EZH2 was carried out using 4 µg mouse monoclonal antibody (Millipore, UK; 17--662), for BRG1 using 5 µg rabbit polyclonal antibody (Santa Cruz sc-10768 (H-88 X) and for diacetylated Histone H3 using 5 µg rabbit polyclonal antibody (Millipore 06--599). Quantitative real-time PCR was carried out using specific and control primers ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}) and the standard curve method as previously described ([@bib40]).

Immunoblotting {#s4-7}
--------------

Immunoblotting was carried out as described previously ([@bib5]; [@bib17]) using anti-BRG1 (Santa Cruz biotechnology, Germany; sc-17796) and anti-actin antibodies (Sigma; A-2066).

Chromosome conformation capture {#s4-8}
-------------------------------

Chromosome conformation capture assays were carried out essentially as described previously ([@bib40]) using *HindIII*-HF (New England Biolabs) with baits consisting of either an 11 kb fragment encompassing the *MYC* promoter, an 18.2 kb fragment encompassing the −556 kb *MYC* SE 3' CTCF site or a 10.8 kb fragment encompassing the *BCL2L11* promoter. Samples were then analysed by semi-quantitative PCR using unidirectional (rather than head to head) primers designed to amplify across ligation junctions ([@bib42]). Positive control PCRs across ligation junctions were carried out using libraries containing genomic DNA fragments representing expected ligation products. Positive control library fragmentswere either synthesised (Genestrings, Life Technologies) or generated from genomic PCR fragments covering the restriction sites of interest that were then digested and ligated. Titrations of positive control DNA were analysed by PCR using the same primers used for chromosome conformation capture to determine the linear range of the assay prior to analysis of the chromosome conformation capture library. Quantitation was carried out using a LiCOR imaging system following agarose gel electrophoresis and staining with GelRed (Biotium, Fremont, California). Interaction frequencies were determined by dividing the chromosome conformation capture chromatin library signal for each ligation junction product by the signal obtained for a positive control sample from within the linear range. Positive control and 3C PCRs were carried out and analysed in duplicate.

Circularised chromosome conformation capture (4C-seq) {#s4-9}
-----------------------------------------------------

*MYC* promoter interacting fragments were captured using a 2.7 kb *NlaIII* fragment encompassing the *MYC* promoter, prior to further digestion by *DpnII* and 4C-seq was carried out using a previously described protocol ([@bib58]). Cells were passed through a 70 µm filter to obtain a single cell preparation. 1 × 10^7^ cells were then fixed in 2% formaldehyde in the presence of 10% FCS for 10 min at room temperature. The reaction was quenched with 0.125 M glycine, and cells collected by centrifugation at 400 g for 8 min at 4°C. The pellet was resuspended in 0.5 ml lysis buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1% Triton X-100) with freshly added complete protease inhibitors (Roche, UK), and lysed on ice for 10 min. The nuclei were collected by centrifugation at 750 g for 5 min at 4°C, then resuspended in 0.5 ml of 1.2X CutSmart Buffer (New England Biolabs) containing 0.3% SDS and incubated for 1 hr at 37°C, while shaking at 900 rpm. Triton X-100 was then added to the nuclei to give a final concentration of 3% and the samples incubated for 1 hr at 37°C, with shaking. 200 U *NlaIII* (New England Biolabs, UK) were added to the nuclei and the samples incubated for 4 hr at 37°C, while shaking at 900 rpm. The reaction was supplemented with a further 200 U *NlaIII* and incubated overnight at 37°C with shaking at 900 rpm. A further 200 U *NlaIII* was added, followed by an additional 4 hr incubation at 37°C while shaking at 900 rpm. The digestion reaction was stopped by incubation at 65°C for 20 min. The sample was then diluted to 7 mls with 1X ligation buffer (Roche). 50 U DNA ligase (Roche) were added to the sample, and the reaction was incubated overnight at 16°C. 300 µg of Proteinase K (Roche) were added to the sample and the reaction incubated at 65°C overnight. RNA was removed by incubation with 300 µg of RNAse for 45 min at 37°C. Following two rounds of phenol-chloroform extraction, DNA was ethanol precipitated prior to resuspension in 150 µl of 10 mM Tris-HCL pH7.5 at 37°C. The samples were then diluted to 500 µl with 1X *DpnII* buffer (New England Biolabs). 50 U *DpnII* (New England Biolabs) were added, followed by an overnight incubation at 37°C whilst shaking at 900 rpm. The digestion reaction was stopped by incubation at 65°C for 20 min. Samples were diluted in 14 mls 1X ligation buffer. 100 U DNA ligase were added and the reaction incubated overnight at 16°C. The samples were then ethanol precipitated in the presence of glycogen at −80°C, prior to purification over a QIAquick PCR purification Kit (Qiagen), and eluted in 150 µl 10 mM Tris-HCL pH7.5.

Fragments captured by the bait region were then amplified by inverse PCR using primers designed to amplify outwards from the bait region ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}). Individual forward primers included a 5' overhang of the Illumina sequence adapter P5 and a unique 'barcode' sequence and encompassed the primary *NlaIII* restriction site of the *MYC* promoter bait. Common reverse primers included a 5' overhang of the Illumina sequence adapter P7 and were designed to bind less than 100 bps from the secondary restriction site (*DpnII*) in the *MYC* promoter bait. PCR was performed using Expand Long Template Polymerase (Roche), with 3.2 µg of template and 1.12 nmol of the P5 and P7 primers for 2 min at 94°C, 10 s at 94°C, 1 min at 55°C, 3 min at 68°C for 29 cycles followed by 5 min at 68°C. 16 individual PCR reactions were carried out for each sample. The reactions were pooled and purified to separate the unused adapter primers from the PCR product using the High Pure PCR Product Purification Kit (Roche). Replicate chromatin samples were generated from the same cell batch and processed separately through each stage. Samples were combined for multiplex 100bp single-end Illumina HiSeq sequencing. Four ER-EB 2.5 LCL samples were sequenced in a single lane using barcodes TSBC01, TSBC02, TSBC10, and TSBC20. Six primary B cell samples were combined in a single lane using barcodes TSBC02, TSBC04, TSBC05, TSBC06, TSBC07, and TSBC12.

4C--sequencing and data analysis {#s4-10}
--------------------------------

Initial data extraction was performed using a custom script (available as a source code file) to strip out and separate embedded barcodes, and to remove reads from the restriction fragment immediately adjacent to the bait, where no digestion had occurred. Reads were mapped to the *Homo sapiens* GRCh37 genome assembly using bowtie 2 v2.2.7 using default parameters, and were filtered to retain only those uniquely mapping reads with MAPQ \>=42. For absolute quantitation the genome was divided into 10 kb windows and quantitated with read counts normalised to the data set with the highest read coverage. For relative quantitation the genome was divided into windows each of which contained a total of 50,000 reads across all samples. Read counts for each region were then quantitated in each individual dataset, and the raw counts were corrected for the total read count to account for differing depths of sequencing. Interaction count differences were calculated by subtracting the normalised counts for one dataset from another. 4C-sequencing data are available via GEO accession GSE82150.
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10.7554/eLife.18270.016

###### Super-enhancers predicted by H3K27ac signal and profile at EBNA2-bound *MYC* enhancers in normal and cancer cells by dbSUPER (<http://bioinfo.au.tsinghua.edu.cn/dbsuper/>^29^).

**DOI:** [http://dx.doi.org/10.7554/eLife.18270.016](10.7554/eLife.18270.016)

10.7554/eLife.18270.017

###### Super-enhancers predicted by H3K27ac signal and profile at EBNA3A or EBNA3C-bound *BCL2L11* enhancers in normal and cancer cells as in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

**DOI:** [http://dx.doi.org/10.7554/eLife.18270.017](10.7554/eLife.18270.017)

10.7554/eLife.18270.018

###### Primers used for 4C and 3C analysis.

**DOI:** [http://dx.doi.org/10.7554/eLife.18270.018](10.7554/eLife.18270.018)

10.7554/eLife.18270.019

###### Primers for ChIP-Q-PCR and RT-QPCR analysis.

**DOI:** [http://dx.doi.org/10.7554/eLife.18270.019](10.7554/eLife.18270.019)

Major datasets {#s7}
--------------

The following dataset was generated:

C David Wood,Hildegonda Veenstra,Sarika Khasnis,Andrea Gunnell,Helen M Webb,Claire Shannon-Lowe,Simon Andrews,Cameron S Osborne,Michelle J West,2016,MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82150>,Publicly available at the NCBI Gene Expression Omnibus (accession number: GSE82150)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*MYC* activation and *BCL2L11* silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Nick Proudfoot as the Reviewing Editor and Jessica Tyler as the Senior Editor. The other reviewers have opted to remain anonymous.

Your referees have discussed their reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essentially your lab\'s study describes the analysis of conformational changes between the promoter and multiple enhancer elements of two key regulatory genes *MYC* and *BCL2L11* following EBV viral infection (especially through expression of EBV encoded transcription factors EBNAs). Your data points to the critical role played by specific EBNAs in reconfiguring enhancer:promoter contacts resulting in *MYC* activation and *BCL2L11* repression. You also provide some interesting mechanistic data on how this occurs mechanistically. Overall all the reviewers found your study interesting but have defined several experimental and presentation weaknesses that will need to be remedied in your revised manuscript. These are listed as follows.

1\) In [Figure 1](#fig1){ref-type="fig"} it should highlighted that the -556 kb enhancer is complex. The 5\' part shows reduced *MYC* promoter interaction following EBNA2 expression. Really, a blow up of this region should be shown in the main figure (as in Figure 1---figure supplement 2). The exact positions of the primers used for [Figure 1G](#fig1){ref-type="fig"} and especially [Figure 1H](#fig1){ref-type="fig"} (showing CTCF interaction) must be shown.

2\) It is claimed from the data of [Figure 3](#fig3){ref-type="fig"} that BRG1 is required for the formation of the EBNA2 induced enhancer:promoter contacts. For this they do an siRNA experiment in GM12878. It would make more sense to do the BRG1 knock-down in the +/- EBNA2 setting. This way direct or indirect effects can be distinguished.

3\) While the data in [Figure 4](#fig4){ref-type="fig"} are interesting as a discussion point, there are no new experiments here to relate the EBNA2 binding sites to these breakpoints. A direct relationship can't therefore be concluded. Consequently we feel that [Figure 4](#fig4){ref-type="fig"} should be removed and the translocation breakpoint connections be referred to in the Discussion.

4\) The initial conformational analysis of the *MYC* locus employed 4C analysis. However the subsequent data relied just on 3C analysis (e.g. [Figure 3D](#fig3){ref-type="fig"}, [Figure 5E](#fig5){ref-type="fig"} and [Figure 6D](#fig6){ref-type="fig"}). We consider that these analyses should be confirmed a more rigorous 4C approach. Also 3C controls should be included such as 3C primers outside the interaction regions as negative controls as well as minus ligase and crosslinking controls. We note that the 4C-seq and differential 4C-seq figures shown are missing y-axes which makes it very difficult to estimate the magnitude of the effect. These should be added

5\) In [Figures 5B, C and D](#fig5){ref-type="fig"}, none of the EBNA3 proteins (A, B or C) ChIP at enhancer 3 above background. Ap and Enhancers 1 and 2 are also very weak for all three EBNA3 factors. How do the authors account for the strong ChIP signals at these enhancers with the general EBNA3 antibody ([Figure 5A](#fig5){ref-type="fig"})? EZH2 is also bound to these sites ([Figure 5F](#fig5){ref-type="fig"}) and so it is not clear that EBNA3 binding is in-fact responsible for the recruitment of EZH2. These issues need consideration and comment.

6\) In [Figure 6](#fig6){ref-type="fig"} UNC1999 needs to be tested in the absence/presence of EBV infection to determine if the effects are dependent on the EBNA3-dependent recruitment of EZH2.

7\) The manuscript should be thoroughly checked for clarity with a view to making the paper understandable to non experts. In particular a clearer description of the different cell types employed would be helpful. Also a final summary figure showing the predicted effects of different EBNAs on *MYC* and *BCL2L11* loci conformations and the key molecular players identified would be desirable.

10.7554/eLife.18270.023

Author response

*1) In [Figure 1](#fig1){ref-type="fig"} it should highlighted that the -556 kb enhancer is complex. The 5\' part shows reduced MYC promoter interaction following EBNA2 expression. Really, a blow up of this region should be shown in the main figure (as in Figure 1---figure supplement 2). The exact positions of the primers used for [Figure 1G](#fig1){ref-type="fig"} and especially [Figure 1H](#fig1){ref-type="fig"} (showing CTCF interaction) must be shown.*

As requested, we have included a blow up of both the -556 and -186/168 *MYC* enhancer regions to highlight their complexity and to indicate the exact positions of the primers used for 3C analysis of *MYC* enhancer and CTCF interactions. These blow ups and the 3C data now form a separate figure, [Figure 2](#fig2){ref-type="fig"}.

*2) It is claimed from the data of [Figure 3](#fig3){ref-type="fig"} that BRG1 is required for the formation of the EBNA2 induced enhancer:promoter contacts. For this they do an siRNA experiment in GM12878. It would make more sense to do the BRG1 knock-down in the +/- EBNA2 setting. This way direct or indirect effects can be distinguished.*

Although it would be nice to perform BRG1 knock-down in the -/+ EBNA2 setting using the conditional EBNA2 cell line (EREB 2.5), this experiment is not possible due to the sensitivity of cells in which EBNA2 has been inactivated. In this cell line EBNA2 activity is controlled through β-estradiol-dependent translocation of the estrogen receptor- EBNA2 fusion protein into the nucleus. In the absence of β-estradiol, EBNA2 is sequestered in the cytoplasm and cannot activate its target genes. Because the growth of EBV-infected B cells is dependent on EBNA2, when EREB2.5 cells are cultured in the absence of β-estradiol, they stop proliferating, undergo cell-cycle arrest and 50% of cells apoptose (Kempkes et al., 1995). It would not be possible to transfect these cells with siRNA as efficient knock-down in B cell-lines requires the use of specialist systems such as the Neon transfection system (Invitrogen) that can be quite toxic to cells. We have optimised efficient BRG1 knock-down using this system in the EBV-immortalised lymphoblastoid cell-line GM12878 and these cells tolerate the procedure well. Neon transfection of sensitive cell lines however, results in substantial cell death. We appreciate that as result, we can only conclude that BRG1 is required for *MYC* enhancer-promoter interactions in EBV-infected cells and we cannot infer that this is an EBNA2-dependent requirement. We have revised the manuscript to make this point more clearly.

*3) While the data in [Figure 4](#fig4){ref-type="fig"} are interesting as a discussion point, there are no new experiments here to relate the EBNA2 binding sites to these breakpoints. A direct relationship can't therefore be concluded. Consequently we feel that [Figure 4](#fig4){ref-type="fig"} should be removed and the translocation breakpoint connections be referred to in the Discussion.*

We have removed [Figure 4](#fig4){ref-type="fig"} as requested and moved the discussion of the potential effects of EBNA2-induced *MYC* enhancer activation on *MYC* translocation breakpoints to the Discussion. We have also re-written the Abstract to move this point to the end.

*4) The initial conformational analysis of the MYC locus employed 4C analysis. However the subsequent data relied just on 3C analysis (e.g. [Figure 3D](#fig3){ref-type="fig"}, [Figure 5E](#fig5){ref-type="fig"} and [Figure 6D](#fig6){ref-type="fig"}). We consider that these analyses should be confirmed a more rigorous 4C approach. Also 3C controls should be included such as 3C primers outside the interaction regions as negative controls as well as minus ligase and crosslinking controls. We note that the 4C-seq and differential 4C-seq figures shown are missing y-axes which makes it very difficult to estimate the magnitude of the effect. These should be added*

We employed 4C to study the effects of EBV on *MYC* promoter-enhancer interactions because of the large number of enhancer binding sites bound by EBNA2 and the very large region involved (3 Mbs). Once key enhancer-promoter interactions had been defined using 4C, we used a 3C approach to confirm the effects of EBNA2 on these interactions. We already included a control region in this 3C analysis (now [Figure 2](#fig2){ref-type="fig"}). We then used 3C to look at the effects of BRG1 knock-down on specific *MYC* interactions (former [Figure 3D](#fig3){ref-type="fig"}, now [Figure 4D](#fig4){ref-type="fig"}). It is a common and acceptable approach to use 3C (and not more 4C) for follow-up experiments, where the effects of specific factors on specific interactions are investigated. We have now included an additional upstream enhancer to increase the scope of this 3C follow-up analysis.

For our analysis of the *BCL2L11* locus we used an entirely 3C-based approach because the location of the three gene promoters and EBNA binding sites at this multi-gene locus was not compatible with 4C strategies we explored using variety of different primary and secondary restriction enzymes. We were however able to delineate the promoters and EBNA3-bound enhancers using 3C, and this enabled us to study the role of individual EBNA 3 proteins using a panel of wild-type and knock-out EBV-infected cell-lines. Examining this number of cell-lines by 4C would not have been cost effective. As requested, we have included additional controls for this 3C analysis. These include three additional controls outside of the interaction regions (the original analysis already included one control region) and a no ligase experiment ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). These additional controls support the specificity of the *BCL2L11* enhancer-promoter and *ACOXL* promoter interactions that we have described.

We have added y axis scale bars to all of the 4C data as requested and fully define these scales in the figure legends, so the magnitude of the effects is clearer.

*5) In [Figures 5B, C and D](#fig5){ref-type="fig"}, none of the EBNA3 proteins (A, B or C) ChIP at enhancer 3 above background. Ap and Enhancers 1 and 2 are also very weak for all three EBNA3 factors. How do the authors account for the strong ChIP signals at these enhancers with the general EBNA3 antibody ([Figure 5A](#fig5){ref-type="fig"}) ? EZH2 is also bound to these sites ([Figure 5F](#fig5){ref-type="fig"}) and so it is not clear that EBNA3 binding is in-fact responsible for the recruitment of EZH2. These issues need consideration and comment.*

ChIP-QPCR sometimes gives slightly different binding profiles to ChIP-seq, but we realise that the key experiment here, rather than looking in the EBV-infected Mutu III BL cell line, is to examine EBNA3 binding in the BL31 cell line series that we used for enhancer analysis. This way, EBNA3 binding can be properly correlated with *BCL2L11* enhancer-promoter interactions and EZH2 levels. We have now carried out ChIP-QPCR analysis in BL31 cells infected with wild-type EBV and confirmed the lack of EBNA3B binding at the *BCL2L11* locus. We also found that EBNA3C bound enhancers 1, 2, 4, 5 and 6 and EBNA3A bound at enhancers 4 and 5 ([Figure 5B, C and D](#fig5){ref-type="fig"}). These data therefore correlate broadly with the Mutu III cell ChIP-seq analysis, where large peaks of binding were seen at enhancers 1 and 2. Little EBNA3A or EBNA 3C binding was detectable by ChIP-QPCR at enhancer 3 and ChIP-seq in Mutu III cells with a pan-EBNA3 antibody detected only a small peak at this site. These new data show that EBNA3 binding does correlate with the increased EZH2 levels detected in the same cell line (now [Figure 6A](#fig6){ref-type="fig"}), although levels of EZH2 are lower at enhancer 2 than at other enhancers.

We would like to clarify however that we did not intend to imply that EBNA3A or EBNA3C recruit EZH2 through a direct interaction, so the binding profiles of these factors may not be expected to exactly correlate. Rather, our data show that EBNA3A and 3C-mediated repression of *BCL2L11* is mediated by enhancer inactivation that likely results from EZH2 recruitment (and increased H3K27me3). There is no evidence that EBNA3A and 3C directly bind to EZH2 or indeed other components of the PRC1 or PRC2 complexes, but there is good evidence that EBNA3A and 3C silencing results in recruitment of PRC complexes and H3K27me3 deposition and is dependent on PRC complex activity. How EBNA3 proteins drive the recruitment of PRC complexes to target genes however is still unclear. There is increasing evidence that EBNA3A and EBNA3C gene silencing may be initiated by the loss of active promoter marks (H3K9ac, H3K27ac and H3K4me3) and that PRC complex recruitment and H3K27me3 may occur subsequently. We have now made this point clearer and added extra discussion of this in the manuscript.

*6) In [Figure 6](#fig6){ref-type="fig"} UNC1999 needs to be tested in the absence/presence of EBV infection to determine if the effects are dependent on the EBNA3-dependent recruitment of EZH2.*

As requested, we have now repeated the EZH2 inhibition experiments using UNC1999 in EBV-negative BL31 cells alongside the BL31 cell line infected with EBV (BL31 wtBAC2) ([Figure 6](#fig6){ref-type="fig"}). These new data show that UNC1999 treatment results in only minor increases in *BCL2L11* expression in uninfected cells compared to the large increases observed in infected cells (where the gene is repressed). The corresponding caspase assays demonstrate that there are large increases in apoptosis in EBV infected cells as a result of UNC1999 treatment that correlate with the increased *BCL2L11* levels. Caspase activity is very low in uninfected cells with only minor increases observed at high UNC1999 concentrations consistent with the small effects on *BCL2L11* expression. These data therefore support our conclusion that EBV-directed *BCL2L11* repression is dependent on EZH2.

*7) The manuscript should be thoroughly checked for clarity with a view to making the paper understandable to non experts. In particular a clearer description of the different cell types employed would be helpful. Also a final summary figure showing the predicted effects of different EBNAs on MYC and BCL2L11 loci conformations and the key molecular players identified would be desirable.*

We have re-written the manuscript to make it clearer to the non-expert by adding extra background information in the Introduction and adding extra explanations of the cell systems used. We have added a final summary figure as requested ([Figure 7](#fig7){ref-type="fig"}).
